膜性肾病
医学
肾病综合征
肾病
蛋白尿
药品
免疫学
肾小球肾炎
内科学
药理学
肾
内分泌学
糖尿病
作者
Rupali S. Avasare,Nicole K. Andeen,Laith Al-Rabadi,Kevin G. Burfeind,Laurence H. Beck
出处
期刊:Journal of The American Society of Nephrology
日期:2025-04-08
标识
DOI:10.1681/asn.0000000719
摘要
Abstract There is a resurgence of interest in drug-induced membranous nephropathy due to the widespread availability of recently discovered culprit medications, such as lipoic acid supplements, mercury in skin lightening creams, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the relationship between these drugs and newly described target antigens. The clinical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria ranges from low-grade to nephrotic-range and generally remits within months of drug cessation. Histology is notable for subepithelial deposits that are immunoglobulin G1 (IgG1) subclass predominant, sometimes with a unique segmental distribution. The two antigens associated with drug-induced membranous nephropathy are neural epidermal growth factor-like 1 (NELL1) and proprotein convertase subtilisin/kexin 6 (PCSK6). Notably, several of the culprit drugs contain one or more sulfhydryl groups that may have potential mechanistic relevance. Here we review past research investigations into mechanisms of membranous nephropathy associated with gold salts, penicillamine, and mercury and use these historical studies as the basis for formulating new hypotheses on how drugs might promote immune dysregulation and, ultimately, membranous nephropathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI